Log In

New? Register Here

Top Biotech & Biopharmaceutical Companies

Google has just Announced a New Health Oriented Company - Calico is a Health Company Focused on Human Health from Extending Life to Increasing Well Being. Read Full Article
Sort By:

Idenix Pharmaceuticals Inc

4th Floor, 320 Bent Street
CAMBRIDGE, MA 02141-2025
http://www.idenix.com/
  • Main Phone: (617) 995-9800
  • Fax Number: (617) 995-9801
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.

Achillion Pharmaceuticals Inc.

300 George Street
NEW HAVEN, CT 6511
http://www.achillion.com
  • Main Phone: (203) 624-7000
  • Fax Number: (203) 624-7003
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.

Progenics Pharmaceuticals Inc.

777 Old Saw Mill River Road
TARRYTOWN, NY 10591
http://www.progenics.com
  • Main Phone: (914) 789-2800
  • Fax Number: (914) 789-2817
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen, a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. In January 2013, the Company acquired Molecular Insight Pharmaceuticals, Inc.

Arena Pharmaceuticals Inc.

6154 Nancy Ridge Drive
SAN DIEGO, CA 92121
http://www.arenapharm.com
  • Main Phone: (858) 453-7200
  • Fax Number: (858) 453-7210
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company s oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, which is in Phase I; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases, and APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain, which is in preclinical development. In June 2012, the United States Food and Drug Administration approved its internally discovered drug, BELVIQ.
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system.

Cytokinetics Inc.

280 East Grand Avenue
SOUTH SAN FRANCISCO, CA 94080
http://www.cytokinetics.com/
  • Main Phone: (650) 624-3000
  • Fax Number: (650) 624-3010
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The Company s research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle. The cardiac muscle contractility program is focused on cardiac sarcomere, the basic unit of muscle contraction in the heart. Its lead drug candidate CK-2017357 is subject of a Phase IIa clinical trials program. CK-2017357 is useful in treating diseases or medical conditions associated with skeletal muscle weakness or wasting. In March 2010, CK-2017357 received an orphan drug designation from the FDA for the treatment of amyotrophic lateral sclerosis.

Alexion Pharmaceuticals Inc.

352 Knotter Drive
CHESHIRE, CT 06410
http://www.alxn.com/
  • Main Phone: (203) 272-2596
  • Fax Number: (203) 271-8198
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.

Gilead Sciences Inc.

333 Lakeside Drive
FOSTER CITY, CA 94404
http://www.gilead.com/
  • Main Phone: (650) 574-3000
  • Fax Number: (650) 578-9264
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.